Afternoon @kpax seems we are all focusing on the future...

Afternoon @kpax seems we are all focusing on the future potential here at SNT.

Parkinson's is extremely tricky , some treatments are pushing for the cleansing of Amyloid Plaque where as SNT 4728 is targeting as a potent Inhibitor of the actual Disease driving enzymes. So you prevent the Enzyme duplication you prevent the establishment of the Disease,,, then a secondary Primary Endpoint would be the Stasis of the Disease (living with Parkinsons but no progression) or the reduction in Disease load ( Reversal of Parkinson symptoms) in the below article there is a word that the medical fraternity almost never use " CURE" that's a high bar to shoot for but obviously would be incredibly valuable,,, I feel any positive data whatsoever will establish a form of value for SNT 4728.





Summary: Syntara Ltd, an Australia-based company, is conducting a phase 2 clinical trial to test SNT-4728, a drug candidate originally developed for other conditions, as a potential neuroprotective treatment to prevent Parkinson’s disease progression in patients with idiopathic REM sleep behavior disorder. The trial, funded primarily by Parkinson’s UK, aims to target neuroinflammation in the disease’s prodromal stage.

Most people with idiopathic REM sleep behavior disorder eventually develop Parkinson’s disease, but an Australia-based clinical drug development company is testing whether a drug candidate originally developed for fatty liver disease and eye disease could prove a viable neuroprotective strategy preventing this distressing progression.

Frenchs Forest, Australia-based Syntara Ltd has recruited 40 patients with idiopathic REM sleep behavior disorder for a phase 2 clinical trial of drug candidate SNT-4728. The double-blind, placebo-controlled trial is majority funded by Parkinson’s UK.

According to company documents, Syntara-discovered SNT-4728 is a potent inhibitor of the enzyme semicarbazide-sensitive amine oxidase and brain monoamine oxidase B.

“If we can successfully treat the neuroinflammation that is driving the disease at the prodromal stage, we could have the chance to

‘cure’

these conditions before people start losing those brain cells,” clinical trial lead-neurologist Simon Lewis


The one part of the Company that is lacking IMHO is Promotion, Market messaging eg where is the ASX Announcement that the Final Dosing will be completed this Month of an International based Phase II Trial surrounding Parkinson??

I'll be blunt , the reason this stock has not smashed through to double digits is the 1, The placement timing with no run up on SNT 5505 and the Market are unaware of the 4 Phase II Candidates this company controls...

Plus Gary dropped into a presentation that Fiona is utilising SNT 6302 on Burns Grafts currently ,, so where is the Market Update..
It's not what Management Know But what the Market knows and understands...$$$ to be made here but SNT should know "You can't Sell and Secret" ... I currently believe we are undervalued by $70m to $100m NZT